Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04254692 · ClinicalTrials.gov registry record · Phase 4

Optimizing Recovery in Abdominoplasty

A Phase 4 study, sponsored by University of Wisconsin, Madison.

Terminated
Registry status
Phase 4
Development phase
2
Enrollment target

NCT04254692 is a Phase 4 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 2 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04254692, a Phase 4 study, was terminated before completion, sponsored by University of Wisconsin, Madison.

TERMINATED
Registry status
Phase 4
Development phase
2 participants
Enrollment target

Study Summary

The overall purpose of this study is to evaluate the analgesic efficacy of liposomal bupivacaine in optimizing pain control, minimizing the risk of postoperative nausea and vomiting (PONV), and improving recovery after abdominoplasty. This will be done by comparing intraoperative abdominal wall and incisional injection of bupivacaine to bupivacaine plus liposomal bupivacaine in 46 participants 18 years and older undergoing elective abdominoplasty. This will be studied using pain assessments, validated surveys, medication logs and review of medical records.

Interventions

  • OTHER Standard of care
  • DRUG Liposomal bupivacaine

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2021-01-05
Est. Completion 2021-01-21
Phase Phase 4

Sponsor

University of Wisconsin, Madison

1,039 total trials

What the Registry Record Tells You About NCT04254692

The ClinicalTrials.gov registry entry for NCT04254692 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.

NCT04254692 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04254692 about?

NCT04254692 is a clinical study titled "Optimizing Recovery in Abdominoplasty". The overall purpose of this study is to evaluate the analgesic efficacy of liposomal bupivacaine in optimizing pain control, minimizing the risk of postoperative nausea and vomiting (PONV), and improving recovery after abdominoplasty. This will be done by comparing intraoperative abdominal wall and ...

What is the current status of trial NCT04254692?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2021-01-05. Estimated completion is 2021-01-21.

What interventions are being tested in trial NCT04254692?

The interventions under investigation include: Standard of care (OTHER), Liposomal bupivacaine (DRUG).

Who is sponsoring clinical trial NCT04254692?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.